Micro Interventional Devices: Creating A Tool Box For Structural Heart Disease

Micro Interventional Devices was founded around opportunities in addressing the procedural challenges that limit patient access to transcatheter heart valves. The company’s initial focus is on developing a transcatheter valve for the replacement of the mitral valve, and an easy and effective transapical access and closure method for transcatheter mitral and aortic valve procedures. The company’s mission, though, is to broadly focus on advancing structural heart disease treatments, and MID’s first-generation technology has potential application to several areas of structural heart disease, including PFO/atrial septal defect closure, left atrial appendage closure and cardiac ablations.

In his 30-year medical device career, Michael Whitman has been involved with several disruptive technologies that have changed the practice of medicine. In 1995 Whitman was working at Johnson & Johnson Interventional Systems Co., the developer and manufacturer of the first coronary stent, when J&J acquired Cordis Corp.[See Deal] and became the market leader in percutaneous coronary intervention. He subsequently founded Power Medical Interventions (PMI), to help advance the evolution of minimally invasive general surgery by developing intelligent surgical instruments to make it easier to do laparoscopic surgeries, including single-port laparoscopy and NOTES (natural orifice transluminal endoscopy.) According to Whitman, “Whenever there is a disruptive or transformative technology, there is often a need to create peripheral devices around it to support it.” He points out that when stents were launched, stent delivery systems had to be improved, and ultimately the stents themselves improved, transforming into drug-eluting stents. Whitman has spent his career working to fill these kinds of gaps. In 2009, after Covidien Ltd. bought Power Medical Interventions, he was looking for the next disruptive opportunity and decided the time was right to create an enabling platform around structural heart disease. [See Deal]

Two years earlier, the first transcatheter aortic valve, Sapien (from Edwards Lifesciences Corp.), had been launched in Europe, and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.